Ovid Therapeutics Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management amended its Schedule 13G filing on Ovid Therapeutics, disclosing a change to its passive stake in the biopharmaceutical company. The filing, submitted to the SEC under accession number 0001346824-26-000289, updates the investor's previously reported position. The amendment signals a shift in the size of RA Capital's holdings, though the filing itself does not indicate an activist intent. Investors will watch for further 13G or 13D filings to gauge whether the change reflects a broader repositioning in the stock.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Ovid Therapeutics Inc., RA Capital Management, L.P.